These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28066191)

  • 21. Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.
    Picconi B; De Leonibus E; Calabresi P
    J Neural Transm (Vienna); 2018 Aug; 125(8):1263-1271. PubMed ID: 29492662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.
    Dwi Wahyu I; Chiken S; Hasegawa T; Sano H; Nambu A
    J Neurosci; 2021 Mar; 41(12):2668-2683. PubMed ID: 33563724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
    Samadi P; Grégoire L; Morissette M; Calon F; Hadj Tahar A; Bélanger N; Dridi M; Bédard PJ; Di Paolo T
    Neuropharmacology; 2008 Feb; 54(2):258-68. PubMed ID: 18001807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
    Belujon P; Lodge DJ; Grace AA
    Mov Disord; 2010 Aug; 25(11):1568-76. PubMed ID: 20623773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.
    Pisanu A; Boi L; Mulas G; Spiga S; Fenu S; Carta AR
    J Neural Transm (Vienna); 2018 Aug; 125(8):1287-1297. PubMed ID: 29541852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
    Sebastianutto I; Cenci MA
    Curr Opin Pharmacol; 2018 Feb; 38():81-89. PubMed ID: 29625424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
    Cote SR; Chitravanshi VC; Bleickardt C; Sapru HN; Kuzhikandathil EV
    Behav Brain Res; 2014 Apr; 263():46-50. PubMed ID: 24462727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's disease.
    Choi H; Koh SH
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):83-90. PubMed ID: 29233065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Johansson PA; Andersson M; Andersson KE; Cenci MA
    Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa treatment and dendritic spine pathology.
    Nishijima H; Ueno T; Funamizu Y; Ueno S; Tomiyama M
    Mov Disord; 2018 Jul; 33(6):877-888. PubMed ID: 28880414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
    Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.
    Santini E; Heiman M; Greengard P; Valjent E; Fisone G
    Sci Signal; 2009 Jul; 2(80):ra36. PubMed ID: 19622833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.
    Nishijima H; Arai A; Kimura T; Mori F; Yamada J; Migita K; Wakabayashi K; Baba M; Ueno S; Tomiyama M
    Neuropathology; 2013 Aug; 33(4):391-6. PubMed ID: 23241013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.
    Cenci MA; Konradi C
    Prog Brain Res; 2010; 183():209-33. PubMed ID: 20696322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.